IJS Oncology is now indexed by ESCI
In conjunction with the Editor-in-Chief, Professor David Rosin, Wolters Kluwer is delighted to announce that IJS Oncology has been accepted for indexing by Clarivate Analytics' Emerging Sources Citation Index (ESCI). This is the first step to gaining an Impact Factor and the Journal will be evaluated for being awarded an Impact Factor in due course.
We would like to thank all authors who have submitted their work to the journal and have contributed to the success of the journal.
Professor David Rosin, Editor-in-Chief
Professor of Surgery, University of the West Indies, Barbados
Past-President of BASO-ACS
Past Vice-President, Royal College of Surgeons of England
The science and practice of oncology is a rapidly developing field. It has become increasingly interdisciplinary through the recognition of the efficacy of combination treatments and multidisciplinary teams. New areas like oncoplastics have been born over the last two decades and risen sharply in both research output and what they mean for approaches to solving complex problems with patients. Similarly advances continue to be made in surgical, medical and radiation oncology. Some cancer therapies are also shifting from a tissue-specific focus to an oncogenetic pathway specific one. Developments in these new paradigms have a long way to go and it is a critical time for the field. Both patient volume and research in this field are increasing rapidly as are diagnostic and prognostic tests, targeted treatments and new practice patterns.
IJS Oncology is a peer-reviewed, international, open access journal seeking to publish in the broad field of oncology, including surgical, medical and radiation oncology. The Journal aims to publish basic science, educational, clinical and translational research articles. We aim to provide rapid submission to decision times whilst maintaining a high quality peer-review process.
To submit to
IJS Oncology, please visit the
Instructions to Authors.